Clinical Characteristics of Pruritus in Systemic Sclerosis Vary According to the Autoimmune Subtype.

Archive ouverte

Gourier, Greta | Théréné, Chloé | Mazeas, Margaux | Abasq-Thomas, Claire | Brenaut, Emilie | Huet, Flavien | Sonbol, Haitham | Campillo, Elize | Lemerle, Julie | Pasquier, Elisabeth | Le Moigne, Emmanuelle | Saraux, Alain | Devauchelle-Pensec, Valérie | Misery, Laurent | Renaudineau, Yves

Edité par CCSD ; Society for Publication of Acta Dermato-Venereologica -

International audience. Pruritus is a frequent symptom in systemic sclerosis (SSc), with a prevalence of 40-65%, but its pathophysiology is poorly understood. This study investigated the immunological component of pruritus. Fifty-six patients with SSc responded to a standardized questionnaire regarding both SSc disease and pruritus characteristics. Among patients with SSc, those with pruritus did not display a particular immunological profile (inflammatory, humoral, and/or cellular factors), but pruritus was, in most cases, concomitant with the development of SSc. Thus, pruritus characteristics were evaluated further, according to the detection of anti-centromere autoantibodies (ACA), into ACA+ (n = 17) and ACA- (n = 19). The ACA+ subgroup was characterized by a longer evolution of SSc and pruritus, pruritus present outside the sclerotic area, and a shorter daily duration of pruritus. In conclusion, the concomitant appearance of the 2 processes and the differences observed between ACA+ and ACA- subgroups support the presence of an immunological component in pruritus.

Consulter en ligne

Suggestions

Du même auteur

Etude du profil immunologique des patients atteints de sclérodermie souffrant de prurit.

Archive ouverte | Gourier, Greta | CCSD

International audience

Le tocilizumab rétabli le turn-over osseux dans la pseudo-polyarthrite rhizomélique récente.

Archive ouverte | Carvajal Alegria, Guillermo | CCSD

International audience

Memory B Cells and Response to Abatacept in Rheumatoid Arthritis.

Archive ouverte | Gazeau, Pierre | CCSD

International audience. Abatacept is a fusion protein (CTLA4-Ig) and therapeutic molecule labeled for the treatment of rheumatoid arthritis (RA). Abatacept acts both by disrupting the CD28-mediated activation of T c...

Chargement des enrichissements...